Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Ovarian Neoplasms

  Free Subscription


1 Am J Surg Pathol
2 Br J Cancer
1 Cancer Res
2 Gynecol Oncol
1 Hum Pathol
1 J Clin Oncol
1 Nat Rev Cancer
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Surg Pathol

  1. NIU S, Lucas E, Molberg K, Strickland A, et al
    Morules but Not Squamous Differentiation are a Reliable Indicator of CTNNB1 (beta-catenin) Mutations in Endometrial Carcinoma and Precancers.
    Am J Surg Pathol. 2022 Jul 14. pii: 00000478-990000000-00041.
    PubMed         Abstract available

    Br J Cancer

  2. OCHS-BALCOM HM, Johnson C, Guertin KA, Qin B, et al
    Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01981.
    PubMed         Abstract available

  3. CHEN Y, Wang DD, Wu YP, Su D, et al
    Correction To: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2022 Sep 15. pii: 10.1038/s41416-022-01984.

    Cancer Res

  4. ZHANG Y, Li J, Zhou Y, Li Z, et al
    And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
    Cancer Res. 2022;82:3249-3262.
    PubMed         Abstract available

    Gynecol Oncol

  5. HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
    Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
    PubMed         Abstract available

  6. YU S, Yang R, Xu T, Li X, et al
    Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
    PubMed         Abstract available

    Hum Pathol

  7. SILVA EG, Lawson BC, Ramalingam P, Liu J, et al
    Precursors in the Ovarian Stroma, Another Pathway to Explain the Origin of Ovarian Serous Neoplasms.
    Hum Pathol. 2022 Apr 12. pii: S0046-8177(22)00087.
    PubMed         Abstract available

    J Clin Oncol

  8. TEW WP, Lacchetti C, Kohn EC
    Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934.
    PubMed         Abstract available

    Nat Rev Cancer

  9. KANDALAFT LE, Dangaj Laniti D, Coukos G
    Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
    Nat Rev Cancer. 2022 Sep 15. pii: 10.1038/s41568-022-00503.
    PubMed         Abstract available

    PLoS One

  10. LIU Y, Liu Q, Jiang X
    Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.
    PLoS One. 2022;17:e0274802.
    PubMed         Abstract available

  11. HEEMSKERK-GERRITSEN BAM, Hollestelle A, van Asperen CJ, van den Beek I, et al
    Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    PLoS One. 2022;17:e0275015.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.